|Bid||0.00 x 1300|
|Ask||0.00 x 3200|
|Day's Range||7.48 - 7.79|
|52 Week Range||3.26 - 8.87|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update VK0214 IND Filed Viking Therapeutics, Inc. (NASDAQ:VKTX) recently announced that the IND for VK0214 has been filed and a Phase 1 trial will commence upon clearance of the IND. The details of the Phase 1 trial will be announced upon study initiation, however we believe the trial will start with a single-ascending
Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups...
Image source: The Motley Fool. Viking Therapeutics (NASDAQ: VKTX)Q2 2020 Earnings CallJul 29, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to the Viking Therapeutics 2020 second-quarter financial results conference call.